|
[1] TSOCHATZIS EA,BOSCH J,BURROUGHS AK. Liver cirrhosis[J]. Lancet,2014,383(9930):1749-1761.
|
|
[2] BLOOM S,KEMP W,LUBEL J. Portal hypertension:Pathophysiology,diagnosis and management[J]. Intern Med J,2015,45(1):16-26.
|
|
[3] ONO H,MAWATARI H,MIZOGUCHI N,et al. Clinical features and outcome of eight infants with intrahepatic porto-venous shunts detected in neonatal screening for galactosaemia[J]. Acta Paediatr,1998,87(6):631-634.
|
|
[4] GARCIA-TSAO G,ABRALDES JG,BERZIGOTTI A,et al.Portal hypertensive bleeding in cirrhosis:Risk stratification,diagnosis,and management:2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology,2017,65(1):310-335.
|
|
[5] BOSCH J,ABRALDES JG,BERZIGOTTI A,et al. The clinical use of HVPG measurements in chronic liver disease[J]. Nat Rev Gastroenterol Hepatol,2009,6(10):573-582.
|
|
[6] SUTTON H,DHAWAN A,GRAMMATIKOPOULOS T. Non-invasive markers of portal hypertension:Appraisal of adult experience and potential utilisation in children[J]. J Pediatr Gastroenterol Nutr,2018,66(4):559-569.
|
|
[7] DU JH,NAN YM. Novel molecular diagnostic markers for liver fibrosis[J]. J Clin Hepatol,2017,33(3):445-450.(in Chinese)杜静华，南月敏．肝纤维化新型分子诊断标志物[J]．临床肝胆病杂志，2017,33(3):445-450.
|
|
[8] LEEMING DJ,KARSDAL MA,BYRJALSEN I,et al. Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension[J]. Aliment Pharmacol Ther,2013,38(9):1086-1096.
|
|
[9] BRUHA R,JACHYMOVA M,PETRTYL J,et al. Osteopontin:A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis[J]. World J Gastroenterol,2016,22(12):3441-3450.
|
|
[10] WANG L,FENG Y,MA X,et al. Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis[J]. PLo S One, 2017, 12(8):e0182969.
|
|
[11] BUCK M,GARCIA-TSAO G,GROSZMANN RJ,et al. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients[J]. Hepatology,2014,59(3):1052-1059.
|
|
[12] SANDAHL TD,McGRAIL R,MOLLER HJ,et al. The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis(ELF)score predicts clinically significant portal hypertension in patients with cirrhosis[J]. Aliment Pharmacol Ther,2016,43(11):1222-1231.
|
|
[13] LISOTTI A,AZZAROLI F,CUCCHETTI A,et al. Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension[J]. Liver international,2016,36(9):1313-1321.
|
|
[14] LIM YL,CHOI E,JANG YO,et al. Clinical implications of the serum apelin level on portal hypertension and prognosis of liver cirrhosis[J]. Gut liver,2016,10(1):109-116.
|
|
[15] FERLITSCH M,REIBERGER T,HOKE M,et al. von Willebrand factor as new noninvasive predictor of portal hypertension,decompensation and mortality in patients with liver cirrhosis[J].Hepatology,2012,56(4):1439-1447.
|
|
[16] HAMETNER S,FERLITSCH A,FERLITSCH M,et al. The VITRO score(von Willebrand factor antigen/thrombocyte ratio)as a new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including ELF test[J]. PLo S One,2016,11(2):e0149230.
|
|
[17] KIM MY,BAIK SK,PARK DH,et al. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis:A prospective nonrandomized study[J]. Liver Int,2007,27(8):1103-1110.
|
|
[18] VIZZUTTI F,ARENA U,REGA L,et al. Performance of Doppler ultrasound in the prediction of severe portal hypertension in hepatitis C virus-related chronic liver disease[J]. Liver Int,2007,27(10):1379-1388.
|
|
[19] ZHU YJ,WANG Y,HUANG JL,et al. Current status and progress in noninvasive assessment of portal pressure[J]. J Clin Hepatol,2014,30(7):608-611.(in Chinese)朱炎杰，王勇，黄家乐，等．门静脉压力的无创性评估现状及进展[J]．临床肝胆病杂志，2014,30(7):608-611.
|
|
[20] RAVAIOLI F,MONTAGNANI M,LISOTTI A,et al. Noninvasive assessment of portal hypertension in advanced chronic liver disease:An update[J]. Gastroenterol Res Pract,2018,2018:4202091.
|
|
[21] IRANMANESH P,VAZQUEZ O,TERRAZ S,et al. Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma[J]. J Hepatol,2014,60(5):969-974.
|
|
[22] QI X,LI Z,HUANG J,et al. Virtual portal pressure gradient from anatomic CT angiography[J]. Gut,2015,64(6):1004-1005.
|
|
[23] HWANG J,KIM Y,LEE W,et al. Unenhanced magnetic resonance portography using repetitive arterial or vein labeling method at 3. 0-T[J]. J Comput Assist Tomogr,2013,37(6):856-861.
|
|
[24] PALANIYAPPAN N,COX E,BRADLEY C,et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging[J]. J Hepatol,2016,65(6):1131-1139.
|
|
[25] WAGNER M,HECTORS S,BANE O,et al. Noninvasive prediction of portal pressure with MR elastography and DCE-MRI of the liver and spleen:Preliminary results[J]. J Magn Reson Imaging,2018,48(4):1091-1103.
|
|
[26] ROLDN-ALZATE A,FRYDRYCHOWICZ A,NIESPODZANY E,et al. In vivo validation of 4D flow MRI for assessing the hemodynamics of portal hypertension[J]. J Magn Reson Imaging,2013,37(5):1100-1108.
|
|
[27] SINGH S,FUJII LL,MURAD MH,et al. Liver stiffness is associated with risk of decompensation,liver cancer,and death in patients with chronic liver diseases:A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol,2013,11(12):1573-1584. e1-e2; quiz e88-e89.
|
|
[28] KONDO R,KAGE M,IIJIMA H,et al. Pathological findings that contribute to tissue stiffness in the spleen of liver cirrhosis patients[J]. Hepatol Res,2018,48(12):1000-1007.
|
|
[29] CASTERA L,PINZANI M,BOSCH J. Non invasive evaluation of portal hypertension using transient elastography[J]. J Hepatol,2012,56(3):696-703.
|
|
[30] DIETRICH CF,BAMBER J,BERZIGOTTI A,et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography,Update 2017(Long Version)[J].Ultraschall Med,2017,38(4):e48.
|
|
[31] BAMBER J,COSGROVE D,DIETRICH CF,et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1:Basic principles and technology[J]. Ultraschall Med,2013,34(2):169-184.
|
|
[32] VIZZUTTI F,ARENA U,ROMANELLI RG,et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis[J]. Hepatology,2007,45(5):1290-1297.
|
|
[33] YOU MW,KIM KW,PYO J,et al. A Meta-analysis for the diagnostic performance of transient elastography for clinically significant portal hypertension[J]. Ultrasound Med Biol,2017,43(1):59-68.
|
|
[34] COLECCHIA A,MONTRONE L,SCAIOLI E,et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis[J]. Gastroenterology,2012,143(3):646-654.
|
|
[35] ELKRIEF L,RAUTOU PE,RONOT M,et al. Prospective comparison of spleen and liver stiffness by using shear-wave and transient elastography for detection of portal hypertension in cirrhosis[J]. Radiology,2015,275(2):589-598.
|
|
[36] SALZL P,REIBERGER T,FERLITSCH M,et al. Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index[J]. Ultraschall Med,2014,35(6):528-533.
|
|
[37] ICHIKAWA S,MOTOSUGI U,MORISAKA H,et al. Comparison of the diagnostic accuracies of magnetic resonance elastography and transient elastography for hepatic fibrosis[J].Magn Reson Imaging,2015,33(1):26-30.
|
|
[38] NIU M,DENG DY,LI YPF,et al. Values of MRE in diagnosis of stages of hepatic fibrosis:A Meta-analysis[J]. J Jilin Univ(Med Edit),2017,43(4):787-793.(in Chinese)牛猛，邓大勇，李云鹏飞，等．磁共振弹性成像对肝纤维化分级诊断价值的Meta分析[J]．吉林大学学报(医学版)，2017,43(4):787-793.
|
|
[39] TALWALKAR JA,YIN M,VENKATESH S,et al. Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension[J]. AJR Am J Roentgenol,2009,193(1):122-127.
|
|
[40] GHARIB AM,HAN M,MEISSNER EG,et al. Magnetic resonance elastography shear wave velocity correlates with liver fibrosis and hepatic venous pressure gradient in adults with advanced liver disease[J]. Biomed Res Int, 2017, 2017:2067479.
|
|
[41] GUO J,BNING C,SCHOTT E,et al. In vivo abdominal magnetic resonance elastography for the assessment of portal hypertension before and after transjugular intrahepatic portosystemic shunt implantation[J]. Invest Radiol,2015,50(5):347-351.
|
|
[42] RONOT M,LAMBERT S,ELKRIEF L,et al. Assessment of portal hypertension and high-risk oesophageal varices with liver and spleen three-dimensional multifrequency MR elastography in liver cirrhosis[J]. Eur Radiol,2014,24(6):1394-1402.
|
|
[43] LLOP E,LOPEZ M,de la REVILLA J,et al. Validation of noninvasive methods to predict the presence of gastroesophageal varices in a cohort of patients with compensated advanced chronic liver disease[J]. J Gastroenterol Hepatol,2017,32(11):1867-1872.
|
|
[44] BERZIGOTTI A,SEIJO S,ARENA U,et al. Elastography,spleen size,and platelet count identify portal hypertension in patients with compensated cirrhosis[J]. Gastroenterology,2013,144(1):102-111. e1.
|
|
[45] COLECCHIA A,RAVAIOLI F,MARASCO G,et al. A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease[J]. J Hepatol,2018,69(2):308-317.
|
|
[46] ABRALDES JG,BUREAU C,STEFANESCU H,et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis:The“Anticipate”study[J]. Hepatology,2016,64(6):2173-2184.
|
DownLoad: